Src Tyrosine Kinase: A Promising Target for Pancreatic Cancer Therapy

A recent study published in Molecular Cancer Therapeutics has highlighted the potential of Src tyrosine kinase as a target for anticancer therapy, particularly in pancreatic cancer. Researchers in the United States investigated the in vivo efficacy and pharmacodynamic effects of bosutinib, a Src/Abl inhibitor, using a panel of human pancreatic tumor xenografts. The study aimed to evaluate the effectiveness of bosutinib in inhibiting tumor growth and analyzing the effects on Src and other pathways.

Key Takeaways:

The study used a panel of 15 human pancreatic tumor xenografts to evaluate the efficacy of bosutinib in inhibiting tumor growth.
Of the 15 patient tumors, 3 patient tumors were found to be sensitive to bosutinib, with tumor growth inhibition observed.
The researchers analyzed Src and other pathways using Western Blot, IHC, and Affymetrix U133 Plus 2.0 gene arrays.
Bosutinib was found to inhibit Src activity in sensitive patient tumors, with a significant reduction in tumor growth.
The study suggests that Src tyrosine kinase is a promising target for pancreatic cancer therapy, with bosutinib showing potential as an anticancer agent.
The researchers conclude that further studies are warranted to fully explore the therapeutic potential of bosutinib in pancreatic cancer.

Statistics:

15 human pancreatic tumor xenografts were used in the study to evaluate the efficacy of bosutinib.
3 patient tumors were found to be sensitive to bosutinib.
Tumor growth inhibition was observed in sensitive patient tumors.
A significant reduction in Src activity was observed in sensitive patient tumors.

Sources:

Messersmith, W.A., et al. (2009). Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Molecular Cancer Therapeutics, 8(6), 1484-1493.
American Association for Cancer Research. (Publisher). Molecular Cancer Therapeutics, 8(6).